Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.6.1.3 (
ATPase
)
65,361
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Erythrocyte membrane Na+/K+, Ca2+/Mg2+ and Mg2+
ATPase
activities in addition to the calmodulin-activated Ca2+/Mg2+
ATPase
enzyme were measured in both G6PD-deficient and normal individuals. Although all three membrane
ATPase
activities were somewhat higher in the G6PD-deficient erythrocytes, only activated Ca2+/Mg2+
ATPase
activity was significantly increased. The effect of primaquine on the membrane ATPases was also compared with other
ATPase
inhibitors.
Primaquine
was ineffective on erythrocyte membrane
ATPase
in-vitro. However, sera containing primaquine metabolite(s) were inhibitory to Ca2+/Mg2+ and Mg2+
ATPase
systems of only G6PD-deficient erythrocytes. Other
ATPase
inhibitors showed a similar inhibitory effect in G6PD-deficient and normal erythrocytes, indicating a specific influence of primaquine on
ATPase
system in G6PD deficiency. It is suggested that this effect of primaquine may be an additional factor for haemolysis observed in the people with GdB- type of G6PD deficiency among the Mediterranean populations.
...
PMID:Erythrocyte membrane ATPase activity of G6PD-deficient individuals and the effect of primaquine metabolite(s) on membrane ATPase enzymes. 615 96
